title: Prediction of endometrial ablation success according to perioperative findings.
abstract: OBJECTIVE
  The aim of this study was to determine which factors in the perioperative period influence the success of endometrial ablation in alleviating menorrhagia.
  
  
  METHODS
  We performed a retrospective chart review of 120 women aged 27 to 49 years who underwent endometrial ablation after 2 months of preoperative treatment with danazol (Danocrine, 800 mg/d orally) or leuprolide (Lupron, 3.75 mg in one intramuscular injection each month). Patients who required medical management or additional operations to control the vaginal bleeding during follow-up (median follow-up, 37 weeks) were considered to have ablation failures.
  
  
  RESULTS
  Sixty-three percent of patients (76/120) had a successful procedure. The chance of success was greater if a cavity of normal appearance was found (odds ratio, 2.3; P =.04). The finding of an intramural fibroid before the procedure resulted in a reduced trend toward success (odds ratio, 0.4; P =.06). The use of danazol pretreatment improved the rate of success overall (odds ratio, 2.2; P =.05) and especially among women <40 years old (P =.01)
  
  
  CONCLUSIONS
  Perioperative findings may provide useful information in counseling patients regarding endometrial ablation. Success is greater among patients with a normal intrauterine cavity and after preoperative treatment with danazol.
authors.affiliation: Departments of Obstetrics and Gynecology and Medical Biostatistics, The University of Vermont College of Medicine, Burlington, VT 05405, USA.
authors.forename: M I
authors.initials: MI
authors.lastname: Shamonki
authors.forename: W F
authors.initials: WF
authors.lastname: Ziegler
authors.forename: G J
authors.initials: GJ
authors.lastname: Badger
authors.forename: C K
authors.initials: CK
authors.lastname: Sites
mesh_terms: D000328:Adult; D003613:Danazol / Q000627:therapeutic use; D004717:Endometrium / Q000601:surgery*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000150:complications* / Q000601:surgery; D016729:Leuprolide / Q000627:therapeutic use; D016015:Logistic Models; D008595:Menorrhagia / Q000209:etiology / Q000601:surgery*; D008875:Middle Aged; D011292:Premedication; D012086:Reoperation; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000150:complications* / Q000601:surgery
chemical_list: D004965:Estrogen Antagonists; D016729:Leuprolide; D003613:Danazol